Tricares Raises €47M In A First Closing Of Its Series C Financing To Fund Further Development Of Minimally Invasive Treatment For Tricuspid Regurgitation

Company

Location

About

TRiCares is developing a transcatheter-based tricuspid valve replacement system aimed at addressing the need for a better treatment for this frequent and severe disease that avoids open heart surgery. Frederik Groenewegen, General Partner at 415 Capital, commented: “TRiCares is developing what we believe has the potential to become a best-in-class therapy option to restore quality of life for millions of patients suffering from tricuspid regurgitation.